Fulltext

Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)

Vehreschild, J. J. ; Böhme, A. ; Cornely, O. A. ; Kahl, C. ; Karthaus, M. ; Kreuzer, K.-A ; Maschmeyer, G. ; Mousset, S. ; Ossendorf, V. ; Penack, O. ; Vehreschild, M. J. G. T. ; Bohlius, J.

In: Annals of Oncology, 2014, vol. 25, no. 9, p. 1709-1718

Ajouter à la liste personnelle
    Titre
    • Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy—evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO)
    Auteur
    • Vehreschild, J. J.. 1st Department of Internal Medicine, University Hospital of Cologne, Cologne
    • Böhme, A.. Onkologikum Frankfurt am Museumsufer, Frankfurt a.M.
    • Cornely, O. A.. 1st Department of Internal Medicine, University Hospital of Cologne, Cologne
    • Kahl, C.. Clinic for Haematology and Oncology, Klinikum Magdeburg gGmbH, Magdeburg
    • Karthaus, M.. Haematology-Oncology and Palliative Care, Hospital Neuperlach and Hospital Harlaching, Munich
    • Kreuzer, K.-A. 1st Department of Internal Medicine, University Hospital of Cologne, Cologne
    • Maschmeyer, G.. Department of Haematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam
    • Mousset, S.. Medizinische Klinik II, University Hospital Frankfurt a.M., Frankfurt a.M.
    • Ossendorf, V.. Clinical Trials Centre Cologne (ZKS Köln, BMBF 01KN1106)
    • Penack, O.. Campus Benjamin Franklin; Medical Clinic for Haematology and Oncology, University Hospital Charité, Berlin, Germany
    • Vehreschild, M. J. G. T.. 1st Department of Internal Medicine, University Hospital of Cologne, Cologne
    • Bohlius, J.. Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Annals of Oncology, 2014, vol. 25, no. 9, p. 1709-1718. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:303384
    Summary
    We found convincing evidence from numerous randomised controlled trials that G-CSF, biosimilar G-CSF and pegfilgrastim reduce the risk to develop febrile neutropenia and infections. As a rule of thumb, it seems the relative benefit is highest for patients with an intermediate risk of infections. Compared to other guidelines, we rated the evidence for growth factors during AML induction chemotherapy and pegfilgrastim use in haematological malignancies lower